Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-05-03

FDA Approved: DEXLANSOPRAZOLE — Supplemental Application (ENDO USA, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for a generic Dexlansoprazole from ENDO USA, Inc., enabling market availability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • DEXLANSOPRAZOLE (DEXLANSOPRAZOLE)

Snippet

SUPPL AP for DEXLANSOPRAZOLE (DEXLANSOPRAZOLE)